Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:CUE

Cue Biopharma Q3 2026 Earnings Date & Estimates

Cue Biopharma logo
$17.04 +0.96 (+5.97%)
Closing price 04:00 PM Eastern
Extended Trading
$17.10 +0.06 (+0.35%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cue Biopharma is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cue Biopharma in Q3 2026

Cue Biopharma is expected to post earnings of -$2.2433 per share on revenue of $1.03 million. In the same quarter a year earlier Cue Biopharma reported -$63.00 per share on revenue of $2.15 million. Cue Biopharma last reported on August 14, 2026, posting -$24.14 per share and missing the -$1.69 consensus estimate.

Consensus Estimates

Consensus EPS
-$2.2433
Expected Revenue
$1.03 million
Prior-Year EPS
-$63.00
Prior-Year Revenue
$2.15 million
Expected Revenue Growth
-51.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$24.14 (Missed by -$22.45)
Last Quarter Revenue
$7.88 million

Prepare for the Q3 2026 Call

Cue Biopharma Q3 2026 Earnings FAQ

Cue Biopharma (NASDAQ:CUE) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Cue Biopharma's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cue Biopharma to post earnings of -$2.2433 per share for Q3 2026.

The consensus revenue estimate for Cue Biopharma is $1.03 million for Q3 2026.

Cue Biopharma Earnings Headlines

REGENXBIO (NASDAQ:RGNX) vs. Cue Biopharma (NASDAQ:CUE) Head to Head Contrast
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109497
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cue-biopharma-cue-reports-hives-034538959.html
Don't lose access to this
Ian Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long. Tradewins plans to move the resource behind a paywall soon, closing off free access to the strategy breakdown. Readers who want a copy should grab it now, before the download link expires.tc pixel
October 20 at 1:00 AM  |  TradeWins (Ad)
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
September 21, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4948441-cue-biopharma-initiating-buy-based-on-cue-221-trial-win-csu-with-novel-dual-moa
Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
September 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cue-biopharma-meets-primary-goal-072620649.html
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
September 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cue-biopharma-shares-jump-41-105525683.html
See More Cue Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cue Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cue Biopharma and other key companies, straight to your email.

About Cue Biopharma

Cue Biopharma (NASDAQ:CUE) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens. Its lead programs have included CUE-101, an investigational therapy designed to stimulate immune responses against HPV16-positive cancers, and CUE-102, which targets the Wilms’ tumor 1 antigen found in several tumor types. The company has also explored additional candidates and applications of its platform in oncology and immune-mediated diseases.

Founded in 2014 and headquartered in Boston, Massachusetts, Cue Biopharma has advanced its candidates through clinical development in the United States. Dan Passeri, a co-founder of the company, has served as its chief executive officer. As a clinical-stage biotechnology company, Cue Biopharma’s programs remain investigational and are subject to clinical and regulatory evaluation.

View Cue Biopharma Profile
Earnings Tools